vs

Side-by-side financial comparison of Citi Trends Inc (CTRN) and NEOGENOMICS INC (NEO). Click either name above to swap in a different company.

Citi Trends Inc is the larger business by last-quarter revenue ($197.1M vs $186.7M, roughly 1.1× NEOGENOMICS INC). Citi Trends Inc runs the higher net margin — -3.5% vs -57.9%, a 54.4% gap on every dollar of revenue. On growth, NEOGENOMICS INC posted the faster year-over-year revenue change (11.1% vs 10.1%). Over the past eight quarters, NEOGENOMICS INC's revenue compounded faster (6.5% CAGR vs -4.3%).

Citi Trends, Inc. is an American retail clothing chain selling discounted products targeted primarily at African-American customers.

NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.

CTRN vs NEO — Head-to-Head

Bigger by revenue
CTRN
CTRN
1.1× larger
CTRN
$197.1M
$186.7M
NEO
Growing faster (revenue YoY)
NEO
NEO
+1.0% gap
NEO
11.1%
10.1%
CTRN
Higher net margin
CTRN
CTRN
54.4% more per $
CTRN
-3.5%
-57.9%
NEO
Faster 2-yr revenue CAGR
NEO
NEO
Annualised
NEO
6.5%
-4.3%
CTRN

Income Statement — Q3 FY2026 vs Q1 FY2026

Metric
CTRN
CTRN
NEO
NEO
Revenue
$197.1M
$186.7M
Net Profit
$-6.9M
$-108.0M
Gross Margin
43.3%
Operating Margin
-3.7%
46.9%
Net Margin
-3.5%
-57.9%
Revenue YoY
10.1%
11.1%
Net Profit YoY
3.6%
42.0%
EPS (diluted)
$-0.86
$-0.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CTRN
CTRN
NEO
NEO
Q1 26
$186.7M
Q4 25
$197.1M
$190.2M
Q3 25
$190.8M
$187.8M
Q2 25
$201.7M
$181.3M
Q1 25
$211.2M
$168.0M
Q4 24
$179.1M
$172.0M
Q3 24
$176.6M
$167.8M
Q2 24
$186.3M
$164.5M
Net Profit
CTRN
CTRN
NEO
NEO
Q1 26
$-108.0M
Q4 25
$-6.9M
Q3 25
$3.8M
$-27.1M
Q2 25
$871.0K
$-45.1M
Q1 25
$-14.2M
$-25.9M
Q4 24
$-7.2M
Q3 24
$-18.4M
$-17.7M
Q2 24
$-3.4M
$-18.6M
Gross Margin
CTRN
CTRN
NEO
NEO
Q1 26
43.3%
Q4 25
43.8%
Q3 25
42.8%
Q2 25
42.6%
Q1 25
43.6%
Q4 24
44.9%
Q3 24
44.6%
Q2 24
44.1%
Operating Margin
CTRN
CTRN
NEO
NEO
Q1 26
46.9%
Q4 25
-3.7%
-7.1%
Q3 25
1.8%
-14.4%
Q2 25
0.2%
-26.3%
Q1 25
0.6%
-16.6%
Q4 24
-4.9%
-10.7%
Q3 24
-14.1%
-12.6%
Q2 24
-3.7%
-13.3%
Net Margin
CTRN
CTRN
NEO
NEO
Q1 26
-57.9%
Q4 25
-3.5%
Q3 25
2.0%
-14.4%
Q2 25
0.4%
-24.9%
Q1 25
-6.7%
-15.4%
Q4 24
-4.0%
Q3 24
-10.4%
-10.5%
Q2 24
-1.8%
-11.3%
EPS (diluted)
CTRN
CTRN
NEO
NEO
Q1 26
$-0.13
Q4 25
$-0.86
Q3 25
$0.46
Q2 25
$0.11
Q1 25
$-1.70
Q4 24
$-0.86
Q3 24
$-2.21
Q2 24
$-0.42

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CTRN
CTRN
NEO
NEO
Cash + ST InvestmentsLiquidity on hand
$146.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$107.8M
$828.8M
Total Assets
$464.3M
$1.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CTRN
CTRN
NEO
NEO
Q1 26
$146.1M
Q4 25
$159.6M
Q3 25
$164.1M
Q2 25
$154.7M
Q1 25
$346.2M
Q4 24
$367.0M
Q3 24
$362.0M
Q2 24
$355.1M
Total Debt
CTRN
CTRN
NEO
NEO
Q1 26
Q4 25
$341.9M
Q3 25
Q2 25
Q1 25
Q4 24
$541.1M
Q3 24
Q2 24
Stockholders' Equity
CTRN
CTRN
NEO
NEO
Q1 26
$828.8M
Q4 25
$107.8M
$836.6M
Q3 25
$113.2M
$838.3M
Q2 25
$108.6M
$854.0M
Q1 25
$113.2M
$888.3M
Q4 24
$130.3M
$902.3M
Q3 24
$136.6M
$908.2M
Q2 24
$154.8M
$915.9M
Total Assets
CTRN
CTRN
NEO
NEO
Q1 26
$1.3B
Q4 25
$464.3M
$1.4B
Q3 25
$457.4M
$1.4B
Q2 25
$437.4M
$1.4B
Q1 25
$462.8M
$1.6B
Q4 24
$467.1M
$1.6B
Q3 24
$506.7M
$1.6B
Q2 24
$484.1M
$1.6B
Debt / Equity
CTRN
CTRN
NEO
NEO
Q1 26
Q4 25
0.41×
Q3 25
Q2 25
Q1 25
Q4 24
0.60×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CTRN
CTRN
NEO
NEO
Operating Cash FlowLast quarter
$8.6M
$-8.1M
Free Cash FlowOCF − Capex
$767.0K
FCF MarginFCF / Revenue
0.4%
Capex IntensityCapex / Revenue
4.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$11.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CTRN
CTRN
NEO
NEO
Q1 26
$-8.1M
Q4 25
$8.6M
$1.3M
Q3 25
$3.9M
$8.9M
Q2 25
$-11.0M
$20.3M
Q1 25
$28.5M
$-25.3M
Q4 24
$-18.4M
$9.8M
Q3 24
$5.6M
$9.2M
Q2 24
$-19.6M
$13.9M
Free Cash Flow
CTRN
CTRN
NEO
NEO
Q1 26
Q4 25
$767.0K
$-6.5M
Q3 25
$-1.7M
$570.0K
Q2 25
$-13.1M
$14.0M
Q1 25
$26.0M
$-29.8M
Q4 24
$-20.4M
$-1.8M
Q3 24
$1.7M
$-1.6M
Q2 24
$-21.2M
$814.0K
FCF Margin
CTRN
CTRN
NEO
NEO
Q1 26
Q4 25
0.4%
-3.4%
Q3 25
-0.9%
0.3%
Q2 25
-6.5%
7.7%
Q1 25
12.3%
-17.8%
Q4 24
-11.4%
-1.0%
Q3 24
0.9%
-0.9%
Q2 24
-11.4%
0.5%
Capex Intensity
CTRN
CTRN
NEO
NEO
Q1 26
Q4 25
4.0%
4.1%
Q3 25
2.9%
4.4%
Q2 25
1.0%
3.5%
Q1 25
1.2%
2.7%
Q4 24
1.1%
6.7%
Q3 24
2.2%
6.4%
Q2 24
0.9%
8.0%
Cash Conversion
CTRN
CTRN
NEO
NEO
Q1 26
Q4 25
Q3 25
1.01×
Q2 25
-12.59×
Q1 25
Q4 24
Q3 24
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons